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Abstract 
Purpose of review 
A wide range of renal replacement therapies is now available to support patients with 
acute kidney injury. These treatments utilize diffusion, convection or a combination of 
these mechanisms to remove metabolic waste products from the bloodstream. It is 
inevitable that physiologically important substances including micronutrients will also 
be removed. Here we review current knowledge of the extent of micronutrient loss, how 
it varies between treatment modalities and its clinical significance. 
 
Recent findings 
Very few studies have specifically investigated micronutrient loss in renal replacement 
therapy for acute kidney injury. Recent data suggest that trace elements and amino 
acids are lost during intermittent dialysis, hybrid therapies such as sustained low 
efficiency diafiltration and continuous therapies. Extent of micronutrient loss appears to 
vary with treatment type, with continuous convection based treatments probably 
causing greatest losses. 
Summary 
Patients with acute kidney injury are at high risk of disease related malnutrition. The 
use of renal replacement therapy, while often essential for life support, results in loss of 
micronutrients into the filtrate or dialysate. Losses are probably greater with 
continuous convective treatments, but it is not yet known whether these losses are 
clinically significant or whether their replacement would improve patient outcomes. 
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Introduction 
Renal replacement therapy (RRT) is required as a supportive treatment in the 
management of patients with severe acute kidney injury (AKI). A range of RRT 
modalities is available, each able to remove metabolic waste products and correct acid-
base abnormalities. In oliguric patients, RRT is also important in achieving fluid balance. 
RRT modalities vary in two basic parameters: (i) duration of treatment, from 
intermittent to continuous and (ii) mechanism of solute clearance: diffusion, convection 
or a combination of the two. The goal of RRT is to remove unwanted molecules from 
blood, but of course diffusion and convection will also remove physiologically important 
molecules such as micronutrients. The extent of such losses will depend on the physical 
properties of the molecule in question and the clearance mechanism of the RRT 
modality. Despite this potential negative aspect of RRT, there has been remarkably little 
research in the area. This is of particular concern given the high risk of malnutrition in 
patients with AKI and critical illness. 
 
Acute Kidney Injury 
AKI is characterized by an abrupt decline in kidney function over hours or days, 
resulting in retention of metabolic waste products and dysregulation of fluid, electrolyte 
and acid-base homeostasis. AKI is a common complication of critical illness and is 
associated with high mortality rate and increased length of hospital stay for survivors. 
AKI is also associated with other adverse patient outcomes, such as development or 
worsening of chronic kidney disease (CKD) and progression to end stage renal disease 
(ESRD). AKI is a syndrome rather than a diagnosis in itself. It can be caused by a wide 
variety of conditions, but most fall into one of the following categories: (i) renal 
ischaemia (including hypovolaemia, haemorrhage and hypotension), (ii) sepsis, (iii) 
nephrotoxins. There is now reasonable international consensus on the definition of AKI 
based on increase in serum creatinine or fall in urine output over specified time. Three 
similar classification systems have been published over the past 10 years: RIFLE, AKIN 
and KDIGO (see [1]* for a recent discussion of AKI definition). 
 
Malnutrition in AKI and critical illness 
There is a high prevalence of disease related malnutrition (DRM) in critically ill patients 
with AKI, which has been identified as an independent predictor of mortality in this 
group [2]. Risk of DRM is high because of (i) reduced intake (due to anorexia, 
malabsorption and reliance on enteral or parenteral prescription), (ii) metabolic 
changes, particularly increased catabolism and (iii) increased losses (gastrointestinal, 
other bodily fluids and losses from RRT). There are far more published studies of 
nutritional status in ICU patients than specifically of patients with AKI requiring RRT, 
though the latter subgroup will share most nutritional risk factors of the former as well 
as having others specific to RRT. A recent comprehensive review of nutrition in critical 
illness was provided by Casaer and Van den Berghe [3]**. 
 
Plasma levels of some micronutrients are affected by the systemic inflammatory 
response syndrome (SIRS). In many cases the plasma or serum level of a micronutrient 
will not represent the overall body status of that substance because of redistribution 
between body compartments. Selenium, for example, is a trace element important in the 
body's response to the oxidative stress of critical illness, essential to the functioning of 
the antioxidant glutathione peroxidase. Plasma selenium levels have been 
demonstrated to be low in critically ill patients and are reported to correlate with 
increased mortality. Ghashut et al [4] investigated the effect of systemic inflammation 
on plasma selenium and zinc levels and demonstrated that their levels were each 
independently associated with CRP and albumin. They concluded that low plasma levels 
do not necessarily reflect true deficiency in the context of SIRS, but that deficiency can 
be inferred in the presence of normal CRP and serum albumin. Stefanowicz et al [5]* 
also concluded that plasma concentrations of selenium, zinc and copper were primarily 
influenced by systemic inflammation rather than a reflection of nutritional status. They 
measured plasma and erythrocyte levels of these trace elements in 125 patients 
admitted to ICU with SIRS. Iglesias et al [6]* studied 173 children admitted to ICU and 
also noted that both malnutrition and elevated CRP were associated with low plasma 
selenium, providing further caution about interpretation of plasma selenium levels. 
 
In some cases, activity of trace element-dependent enzymes may offer a more accurate 
means of determining tissue trace element status. Combs reviewed biomarkers of 
selenium status in considerable detail and discussed markers of intake, retention, tissue 
levels and function [7]*. Activity of the glutathione peroxidases GPX1 (in erythrocytes) 
and GPX3 (extracellular) may reflect selenium tissue status but interpretation of results 
is again complex because of genetic variation in enzyme activity. Furthermore, assaying 
enzyme activity is likely to be of use only in states of selenium deficiency, rather than 
being able to stratify higher levels of tissue selenium. Biomarkers of copper status are 
probably even less adequate. Danzeisen et al reviewed this subject in 2007 [8]. It was 
known then that plasma copper does not reflect copper status, nor do cuproproteins 
such as ceruloplasmin (which may reflect severe depletion but does not stratify 
adequate or excessive levels). The cuproenzymes superoxide dismutase (SOD) 1 and 3 
have proved to be poor biomarkers of copper status but the copper chaperone for SOD 
(CCS) has some advantages. Further discussion of biomarkers of micronutrient status is 
beyond the scope of this review but there is a parallel between these and novel AKI 
biomarkers.  There has been considerable clinical and commercial interest in each of 
these fields over the past 10 years, with numerous candidate biomarkers but none 
fulfilling its early promise so far.  
 
Similarly, urinary levels of micronutrients do not seem to provide reliable information 
about overall status of a given micronutrient. In some cases urinary levels reflect recent 
intake but in many cases not even that, because of numerous confounding factors 
affecting urinary excretion. For example, Fukuwatari and Shibata demonstrated that, for 
8 out of 9 water soluble vitamins that they tested, 24-hour urinary excretion correlated 
with intake [9]. Knowledge of urinary excretion of micronutrients in health and disease-
related malnutrition is important when considering whether losses from other routes, 
including RRT, are likely to be excessive and clinically relevant. 
 
Renal Replacement Therapy in AKI 
In modern renal and intensive care units, a wide range of RRT types is available for 
supporting patients with AKI, varying in duration of therapy and mechanism of solute 
removal. The two most commonly used techniques lie at opposite ends of the spectra 
for both duration and clearance mechanism. Intermittent haemodialysis (IHD) is a 
diffusion-based treatment where blood and dialysate flow countercurrent at relatively 
high pump speeds, separated by a semipermeable membrane, usually in the form of 
thousands of synthetic capillaries within the dialyser. It is used for a few hours daily or 
on alternate days. Continuous veno-venous haemofiltration (CVVH) is convection based, 
with solutes being removed with filtrate as a consequence of pressure being applied 
across the capillary membrane within the haemofilter. Physiologically appropriate 
replacement fluid is required, in view of the relatively large volume of filtrate lost. In 
principle, the process continues without interruption for >24 hours. RRT techniques are 
now available which cover most of the possible permutations of duration and clearance 
mechanism including 'hybrid' treatments such as sustained low efficiency diafiltration 
(SLEDf), which is used typically for 8-12 hours daily and utilizes both diffusion and 
convection. It is essentially slow dialysis (i.e. slow blood and dialysate pump speeds) 
with an element of filtration in addition. 
 
There is ongoing debate about which RRT modality is best, but in terms of hard 
outcomes such as mortality and renal recovery after AKI, there is not yet any convincing 
evidence that any one modality is superior. A recent review of RRT in AKI by Ronco et al 
addresses some of the options and controversies [10]*. In practice, choice of RRT 
modality is usually influenced by local facilities and experience. IHD is used 
predominantly in renal units and continuous RRT (CRRT) methods such as CVVH 
predominantly in intensive care units. CRRT is usually favoured in the presence of 
hypotension or haemodynamic compromise. A recent survey of RRT use in general 
adult ICUs in the United Kingdom demonstrated highly variable practice, reflecting the 
lack of evidence to support RRT prescription for AKI [11]. Peritoneal dialysis (PD) is 
rarely used to treat AKI in developed countries where extracorporeal RRT methods are 
widely available, but is sometimes used in children and occasionally in adults where 
there are significant problems with vascular access or haemodynamic stability. 
 
Micronutrient loss in CRRT 
Diffusion based RRT (dialysis) in general is more efficient at clearing small molecules, 
whereas larger molecules are removed by convective treatments, up to a point, 
depending on pore size of the haemofilter membrane and solute size. For example, 
hyperkalaemia is treated more efficiently with IHD than CVVH because potassium is a 
small cation and diffuses down a concentration gradient (from blood to dialysate) 
quickly. In contrast, some inflammatory mediators such as cytokines are more likely to 
be removed by CVVH, but would be too large for effective removal by diffusion. The 
same principles apply when considering loss of micronutrients during RRT. In practice, 
losses are more difficult to predict because of the wide range of RRT modalities now 
available and the complex interaction of associated variables such as pore size and 
thickness of the dialysis (or haemofilter) membrane, pump speed for blood and 
dialysate, proportion of plasma water removed (filtrate). Diffusion based treatments 
will also involve a degree of convection if fluid is removed during the treatment, so it is 
difficult to compare pure diffusion with pure convection in a clinical study. 
 
Very few published studies have quantified micronutrient losses in RRT for AKI and all, 
so far, have involved low numbers of patients. Few have compared micronutrient losses 
between RRT modalities or investigated losses in newer hybrid treatments such as 
SLEDf. In general, nutritional status of patients with CKD including ESRD has been 
studied far more extensively than nutritional status of patients with AKI. The same 
applies to studies of micronutrient loss in RRT, with far more data available for ESRD. 
These data may be of some use in formulating hypotheses for losses in RRT for AKI, but 
should be treated with caution. AKI and ESRD are very different conditions, with 
different metabolic profiles and nutritional problems; ideally they should be studied 
independently. Amino acid losses from CRRT in patients admitted to ICU have been 
investigated occasionally in small studies over the past 25 years. The interest relates to 
concerns about negative nitrogen balance in critically ill patients, as a contributing 
factor to malnutrition. Btaiche et al [12] reviewed 8 small studies conducted between 
1991 and 2003 involving different types of CRRT (3 studies included the outdated 
technique of continuous arterio-venous haemofiltration, CAVH). Most of the studies 
included fewer than 10 patients, but they did demonstrate that all types of amino acid 
were cleared in the filtrate, that losses correlate with serum amino acid levels and with 
clinical condition (e.g. greater losses with cardiogenic shock). CVVH resulted in 30-40% 
greater losses than continuous veno-venous haemodialysis (CVVHD, diffusion-based, 
with very low blood and dialysate pump speeds). More recently, Umber et al [13] 
quantified amino acid losses in 5 critically ill patients treated with sustained low 
efficiency dialysis (SLED, a diffusion-based treatment). They reported amino acid losses 
comparable to those previously reported for CVVH, with a median loss of 15.7g per 
treatment. 
 
Such small and dated studies need to be interpreted with caution, but the results appear 
generally consistent with preliminary data from a relatively large study from our group 
in Nottingham. We have completed recruitment of 72 patients requiring RRT for AKI 
and investigated losses of amino acids, trace elements and B-vitamins. We compared 
losses between 3 types of RRT: CVVH, SLEDf and IHD i.e. a continuous convective 
treatment, an intermediate-duration convective and diffusion-based treatment and an 
intermittent diffusion-based treatment, respectively. Data have been published only in 
abstract form so far but demonstrate significant losses of amino acids and trace 
elements, greatest in CVVH [14]*. We are not aware of any other recent adequately 
sized studies that have investigated losses of trace elements or water soluble vitamins 
in RRT for AKI. Kosmadakis et al [15]* published a detailed review of vitamins in 
dialysis for ESRD, including discussion of roles, requirements and losses from 
treatment. Shaban et al [16] have also recently reviewed measurement of vitamins and 
trace elements in ESRD; Filler and Felder [17] reviewed trace elements in the context of 
children requiring chronic dialysis and recommended regular assessment of 9 different 
trace elements, though the evidence to support this is currently sparse and the 
population reviewed is very different from critically ill adults with AKI. 
 
Replacement of micronutrients 
Demonstrating deficiency of micronutrients in patients with AKI is clearly not the same 
as demonstrating a clinical benefit from supplementation. Indeed many micronutrients 
are potentially toxic in excess or in certain circumstances e.g. plasma catalytic iron (i.e. 
circulating iron not bound to transferrin or other proteins) levels appear to be 
associated with increased risk of AKI, RRT and mortality in patients admitted to ICU 
[18]*. Whether this association is causative is not clear. Glutamine supplementation has 
been a controversial subject in intensive care medicine for several years. It has been 
considered a 'conditionally essential' amino acid in critically ill patients, on the basis 
that, with muscle wasting, glutamine production might not meet increased 
requirements for important roles such as immune cell functioning. Low glutamine levels 
have been associated with poor outcome in critical illness, but well-designed 
randomized controlled trials have not shown any benefit of glutamine supplementation 
[19, 20]. In fact the REDOXs study [20] suggested that early high dose (parenteral and 
enteral) glutamine supplementation was harmful. A post-hoc analysis revealed that 28 
day mortality was significantly higher only in the subgroup of patients receiving 
glutamine supplementation who had baseline renal impairment but did not receive RRT 
[21]*. The inclusion of a relatively large proportion of patients with renal impairment in 
this study contrasted with most of the previous studies investigating glutamine 
supplementation in critical illness and might explain in part the different results. The 
parenteral glutamine supplement used in this study was the synthetic dipeptide L-
alanyl-L-glutamine, which the manufacturers suggest should not be used where GFR is 
less than 25 mL/min, because of the possibility of aggravation of uraemia. A recent 
review of the subject concluded that supra-physiological doses of glutamine should not 
be given to critically ill patients with multi-organ failure including low GFR [22]. It 
remains unclear how glutamine supplementation should be used optimally, in terms of 
timing, dosing and patient subgroups. 
 
Various other non-renal ICU based studies have failed to demonstrate benefit of 
micronutrient supplementation. Landucci et al [23] undertook a systematic review of 9 
RCTs investigating selenium supplementation in critically ill adults and suggested a 
possible albeit rather unconvincing beneficial effect on 28 day mortality. Despite lack of 
data to support routine micronutrient supplementation, macro- and micronutrients are 
often routinely administered intravenously in the acute phase of critical illness on the 
basis that the benefits, such as reducing risk of refeeding syndrome, are likely to 
outweigh the risks. For those patients with AKI requiring RRT, it is not known whether 
additional micronutrient supplementation to compensate for RRT losses improves 
outcomes. It is routine practice to prescribe regular supplements of water soluble 
vitamins to patients with ESRD receiving regular haemodialysis, but even in this more 
extensively studied group, there is little evidence of improvement in hard outcomes 
such as mortality [24, 25*]. 
 
Conclusion 
Patients with severe AKI requiring RRT have a high risk of disease related malnutrition. 
True deficiency is difficult to assess in the case of many micronutrients because blood 
levels may not represent overall body status. There is evidence that micronutrients are 
lost in effluent (dialysate or filtrate), which might be anticipated from knowledge of the 
physical properties of the molecules and the mechanisms of their clearance. These 
losses have been quantified to some extent in a few small studies, mostly involving 
CVVH. One ongoing relatively large study is seeking to compare micronutrient losses 
between 3 commonly used RRT modalities. It is likely that certain micronutrients might 
be lost during RRT by adsorbing to the haemofilter rather than by filtration, but this 
mechanism has not been studied adequately to date. Two far more important questions 
remain unanswered: (i) do these micronutrient losses result in clinically significant 
consequences and (ii) would replacement of calculated losses, perhaps tailored to 
individual patients and RRT modalities, result in improved outcomes? Large well 
designed clinical trials will be required to answer these questions. Considering the high 
risks of mortality and morbidity associated with severe AKI, and the huge costs to the 
health service [26]** it is surprising that nutrition research in AKI has attracted so little 
interest to date. 
  
Key points 
 Renal replacement therapy is a route of micronutrient loss in patients with acute 
kidney injury 
 The extent of micronutrient losses varies with the type of RRT 
 It is not yet clear if these losses are clinically significant and whether they should 
be accounted for when calculating a patient's nutritional requirements 
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